Navigation Links
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Date:1/15/2009

INDIANAPOLIS, Jan. 15 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has reached resolution with the United States Attorney for the Eastern District of Pennsylvania (EDPA) and the Office of Consumer Litigation of the Department of Justice regarding the previously-reported government investigation into the company's past U.S. marketing and promotional practices for the antipsychotic medication Zyprexa(R) (olanzapine).

Lilly has been cooperating with the government in its investigation since it began in 2004. As part of the resolution, Lilly has agreed to plead guilty to one misdemeanor violation of the Food, Drug, and Cosmetic Act. The company will also enter into a settlement agreement resolving the federal government's civil investigation. Even though the company disagrees with and does not admit to the civil allegations, the company has agreed to settle the dispute over these allegations. In addition, the company has agreed to settle civil investigations brought by the State Medicaid Fraud Control Units of the states that have coordinated with the EDPA in its investigation.

"We deeply regret the past actions covered by the misdemeanor plea," said John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Lilly. "At Lilly we take seriously our responsibilities to abide by all the laws governing our business practices, and we realize that we have a tremendous responsibility to the patients and healthcare professionals we serve. Every day and with every interaction we strive to operate in a responsible and compliant manner. Doing the right thing is non-negotiable at Lilly, and I remain personally committed to all of us at Lilly maintaining the highest standards of conduct."

Continued Lechleiter, "The company's comprehensive compliance prog
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Lilly Files Form 8-K/A Detailing Pro Forma Impact of ImClone Acquisition
2. Lilly Sets Date and Conference Call for Fourth-Quarter and Full-Year 2008 Financial Results Announcement
3. Lilly Announces Dividend Increase
4. Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies
5. Lilly Global Day of Service Receives National and Local Recognition
6. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
7. Lilly Completes Acquisition of ImClone Systems
8. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
9. Lilly Offers Free Health Guide, Available throughout State
10. Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center
11. Lilly Announces Major Donation of Insulin to International Diabetes Federations Life for a Child Program; Initial Focus Will Be on Sub-Saharan Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... has become a mainstay of multiple myeloma treatment ... system of patients who have received stem cell ... early clinical trial results to be presented by ... American Society of Hematology,s (ASH) annual meeting on ... Convention Center, Room 243-245, 5:45 pm CT). , ...
(Date:12/6/2009)... by researchers from the Medical College of Wisconsin, in ... pain and other sickle cell disease complications in children. ... providers and patients were also identified. The study ... of pediatrics at the Medical College and Children,s Research ... presented at the American Society of Hematology meeting Dec. ...
(Date:12/6/2009)... 2009 A new study provides welcome news for ... thromboembolism (VTE). , The condition is estimated to ... occurs when an abnormal clot forms in a vein ... swelling. In some cases, the clot may detach from ... to the lungs, causing a potentially fatal condition known ...
(Date:12/5/2009)... combination has shown in a phase 1/2 clinical ... the treatment of patients newly diagnosed with multiple myeloma, ... say researchers from Dana-Farber Cancer Institute. , Partial responses ... patients treated with the drug combination in the multi-center ... response rate" in the phase 2 population, reports Paul ...
(Date:12/5/2009)... Blood Cancer Is Most Challenging-- ,, PHILADELPHIA ... identified specific genes, dubbed partner genes, that fuse with ... in infants. By more accurately defining specific partner genes, ... from particular treatments. ,, Oncologists also aim to ...
Breaking Medicine News(10 mins):Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4
... of the threats to themselves and relatives, study says , , ... of families in which some members have BRCA1 or 2 ... ovarian cancer -- typically avoid genetic counseling or testing, a ... testing, they,re less likely than women to pass on the ...
... provide 50 free colonoscopies to patients impacted by the recent economic ... ... -- On Saturday, March 14, the physicians at Digestive Health Specialists ... screening colonoscopies to help those in our communities who have recently ...
... Included in Study Not Atkins DietDENVER, Feb. 27 ... (NEJM) study titled "Comparison of Weight-Loss Diets with ... 26, 2009), concluded that reduced-calorie diets result in ... (fat, protein and carbohydrates) they emphasize. Atkins ...
... surgeons at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis are reporting that artificial discs ... , Click here for more information. , ... , , , ... , , , ...
... FindingsNEWPORT NEWS, Va., Feb. 27 Women facing a ... the same or opposite breast with further testing using ... in the February 2009 "American Journal of Surgery." BSGI ... same or opposite breast in 10.9 percent of newly ...
... New Innovations and Technologies Aimed at Dentists and ConsumersCHICAGO, ... professionals will get a first look at the latest ... Midwinter Meeting. Held February 26 through March 1 at ... more than 570 exhibiting companies from around the world. ...
Other Medicine News:Health News:Men With BRCA Gene Mutations Unaware of Cancer Risks 2Health News:Men With BRCA Gene Mutations Unaware of Cancer Risks 3Health News:Local Gastroenterology Practice Gives Back to the Community During Colon Cancer Awareness Month 2Health News:Atkins Responds to Recent New England Journal of Medicine Weight-Loss Diets Study Results 2Health News:Atkins Responds to Recent New England Journal of Medicine Weight-Loss Diets Study Results 3Health News:Artificial disc replacement as good or better than spinal fusion surgery 2Health News:Artificial disc replacement as good or better than spinal fusion surgery 3Health News:Artificial disc replacement as good or better than spinal fusion surgery 4Health News:Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients 2Health News:Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients 3Health News:One of North America's Largest Exhibitions of Dental Products Brings More than 30,000 Dental Professionals to Chicago 2Health News:One of North America's Largest Exhibitions of Dental Products Brings More than 30,000 Dental Professionals to Chicago 3
(Date:12/4/2009)... inexpensive computer tool that measures volume changes in the ... by a CT scanner can rule out non-cancerous ones ... true cancers with fewer, less expensive and less invasive ... diagnostic guidelines are described in a paper published yesterday ...
(Date:12/4/2009)... Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) announced that on ... Reorganization and related amended Disclosure Statement with the United States ... A hearing to consider the adequacy of the Disclosure Statement ... on the confirmation of the Plan scheduled for January 7, ...
(Date:12/4/2009)... 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... and webcast. Principal investigators will discuss the data ... as featured at the 51st American Society of Hematology ... 9:00 a.m. CT/10:00 a.m. ET on Monday, December 7, ...
Breaking Medicine Technology:European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex 28R 29 12913 1China Clean Energy Provides Business Update 12912 1China Clean Energy Provides Business Update 12912 2China Clean Energy Provides Business Update 12912 3US Farms Inc Showcasing Aloe Vera Product Line at Natural MarketPlace 2009 50872 1US Farms Inc Showcasing Aloe Vera Product Line at Natural MarketPlace 2009 50872 2
... able to stimulate insulin,release, TARRYTOWN, N.Y., March ... today results of two clinical,studies conducted in ... Gastroenterology and Hepatology,University Hospital Basel in Basel, ... peptide-1 (7-36 amide) (GLP-1) was to,establish the ...
... Survey Shows 89% of Patients Prefer Orapred ... 2007 /PRNewswire/ -- Alliant,Pharmaceuticals announced today survey ... sodium phosphate,orally disintegrating tablets) over liquid steroids.(1) ... survey involving more than,900 children (n=973), showed ...
Other Medicine Technology:Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 2Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 5Orapred ODT Tastes Good 2Orapred ODT Tastes Good 3
... an integral part of the enzymatic cascade ... as well as the degradation of Bradykinin. ... is primarily located in endothelial cells. ACE ... for sarcoidosis and myocardial infarction but is ...
... and quantitative evaluation of pancreatic b-cell function is ... post-diagnostic study of the natural history of diabetes ... as a guide to the correct choice of ... to assess b-cell function because of the ...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
... quantitative evaluation of pancreatic -cell function is not ... study of the natural history of diabetes mellitus, ... a guide to the correct choice of treatment. ... -cell function because of the large and variable ...
Medicine Products: